Daiichi Sankyo, Merck
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer. The drug helped patients live significantly longer without their cancer progressing,
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial as a second-line therapy. Read more here.
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study,
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing in a late-stage study.
After FDA no, MSD/Daiichi post new data with lung cancer ADC
The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC) was turned down by the FDA in June as a third-line or later treatment for locally advanced or metastatic EGFR-mutated NSCLC because of problems at a third-party manufacturer.
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.
NHS England to offer Daiichi Sankyo’s quizartinib for AML
The UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
FiercePharma2d
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...
FierceBiotech3d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
pharmaphorum1d
Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia
NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...
FiercePharma13h
Daiichi, AZ's first Enhertu DTC campaign kicks off during Thursday Night Football
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
devdiscourse1d
Recent Health Developments: Affordable Medicines, Breakthrough Devices, and Global Campaigns
This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
In the trial, most interstitial lung disease events were observed to be low grade, with two grade 5 ILD events being reported ...